Objective: To determine drug compliance among patients with rheumatological and musculoskeletal diseases and to identify the reasons behind poor compliance. Study Design: Cross-sectional study. Place and Duration of Study: Department of Rheumatology Lady Reading Hospital, Peshawar Pakistan, from Aug 2020 to Feb 2021. Methodology: All patients aged 16 to 70, of either gender with inflammatory rheumatic diseases who were prescribed conventional DMARDs for at least six months were included in the study. Results: Two hundred and eighteen patients were included in the study. There were 59(27.1%) males and 159(72.9%) females with a mean age of 38.56±4.75years. There were 156 SPRA patients (71.5%), while SLE and SNIA accounted for 22(10.1%) and 17(7.8%) cases, respectively. Methotrexate was the most commonly prescribed medicine, 158(72.5%) while 90(41.3%) patients were prescribed Hydroxychloroquine and 43(19.7%) patients were prescribed Sulfasalazine. Regarding compliance, 112 (51.4%) patients were found to have good drug adherence. On the other hand, side effects and lack of awareness were found to be the most common cause of poor medication adherence. Conclusion: We concluded that adherence to medication among patients with inflammatory rheumatic and musculoskeletal diseases is poor
Objective: To investigate the frequency of Depression in Patients with Rheumatic and Musculoskeletal diseases with particular emphasis on gender and compliance to treatment. Study Design: Descriptive, Cross-sectional study. Setting: Department of Rheumatology at Lady Reading Hospital, Peshawar. Period: August 2020 to February 2021. Material & Methods: A total of 189 patients were assessed with their detailed history, examination, and lab data collected. Depressive symptomatology was evaluated using DSM – 4 criteria . SPSS 26 was utilised for data analysis, and a p-value of<0.05 was considered statistically significant. Results: 131 (69.3%) were female and 58 (31.7%) were male patients. Seropositive Rheumatoid Arthritis ranked the highest concerning the diagnosis with 128 cases (68.25%). Methotrexate was the most commonly used drug with 134 (70.9%) patients receiving it. A total of 169 (89.4%) patients had Depressive disorder, with females outnumbering males, a finding reaching statistical significance (p=0.04). Conclusion: Undiagnosed Depression is common in patients affected by Rheumatic and Musculoskeletal diseases, especially among the female population. Routine screening for depressive symptoms with subsequent referral to the mental health service may serve detection of this comorbidity and improve patient outcomes.
Objective: To determine the frequency of different neuropsychiatric manifestations of systemic lupus erythematosus Study Design: Cross-sectional study. Place and Duration of Study: Division of Rheumatology Lady Reading Hospital, Peshawar Pakistan, from Sep 2020 to Feb 2021. Methodology: 31 patients who fulfilled the 2019 ACR/EULAR criteria for SLE diagnosis were included in the study. Different features of neuropsychiatric manifestations of systemic lupus erythematosus were recorded on a proforma. Results: Our study sample included 27 females and four males. Most of the patients were young, with a mean age of 23.12 ± 10.74 years. All patients had positive Anti-nuclear antibodies (100%), while anti-double standard DNA antibody was found in 21 patients (67. 74%). Seizures were the most common neuropsychiatric feature, i.e., found in 18 patients (58%), followed by headache (25.8%), acute confusional state (25.8%) and CNS demyelinating disease (19.3%). Conclusion: We found that seizures, headache and acute confusional state were the most common neuropsychiatric manifestations of systemic lupus erythematosus.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.